Shares of Catalent Inc (NYSE:CTLT) have been assigned a consensus rating of “Buy” from the fourteen research firms that are currently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $49.50.
Several equities research analysts have recently commented on the stock. ValuEngine raised shares of Catalent from a “hold” rating to a “buy” rating in a research report on Tuesday, June 26th. Zacks Investment Research lowered shares of Catalent from a “buy” rating to a “hold” rating in a research report on Tuesday, July 3rd. JPMorgan Chase & Co. upped their price target on shares of Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Wednesday, August 29th. Finally, UBS Group assumed coverage on shares of Catalent in a research report on Tuesday, October 9th. They set a “neutral” rating and a $48.00 price target for the company.
In other news, Director Donald E. Morel, Jr. bought 10,000 shares of Catalent stock in a transaction that occurred on Thursday, September 13th. The stock was bought at an average cost of $43.00 per share, with a total value of $430,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, SVP Lance Miyamoto sold 6,525 shares of the stock in a transaction that occurred on Tuesday, October 16th. The stock was sold at an average price of $42.50, for a total transaction of $277,312.50. The disclosure for this sale can be found here. Insiders sold a total of 184,335 shares of company stock valued at $8,161,727 over the last three months. 1.40% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its holdings in Catalent by 4.3% in the 2nd quarter. Janus Henderson Group PLC now owns 6,400,737 shares of the company’s stock worth $268,127,000 after acquiring an additional 266,183 shares in the last quarter. FMR LLC grew its holdings in Catalent by 1.5% during the 2nd quarter. FMR LLC now owns 3,781,793 shares of the company’s stock valued at $158,420,000 after buying an additional 54,678 shares in the last quarter. American Century Companies Inc. grew its holdings in Catalent by 6.4% during the 2nd quarter. American Century Companies Inc. now owns 3,052,515 shares of the company’s stock valued at $127,870,000 after buying an additional 183,880 shares in the last quarter. Earnest Partners LLC grew its holdings in Catalent by 0.3% during the 2nd quarter. Earnest Partners LLC now owns 2,548,094 shares of the company’s stock valued at $106,740,000 after buying an additional 7,628 shares in the last quarter. Finally, Macquarie Group Ltd. grew its holdings in Catalent by 25.2% during the 2nd quarter. Macquarie Group Ltd. now owns 2,349,059 shares of the company’s stock valued at $98,402,000 after buying an additional 472,228 shares in the last quarter. 91.78% of the stock is owned by institutional investors.
CTLT traded down $0.04 during midday trading on Wednesday, hitting $41.33. 388,523 shares of the company traded hands, compared to its average volume of 932,208. The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.79 and a current ratio of 2.15. The stock has a market capitalization of $6.01 billion, a P/E ratio of 25.98, a P/E/G ratio of 2.46 and a beta of 1.40. Catalent has a 52 week low of $36.73 and a 52 week high of $47.87.
Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, August 28th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.61 by $0.06. The business had revenue of $685.30 million for the quarter, compared to analysts’ expectations of $690.69 million. Catalent had a net margin of 3.39% and a return on equity of 20.42%. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.65 EPS. Research analysts forecast that Catalent will post 1.72 EPS for the current fiscal year.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More: What is the NASDAQ Stock Market?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.